Literature DB >> 33220257

NMIIA promotes tumorigenesis and prevents chemosensitivity in colorectal cancer by activating AMPK/mTOR pathway.

Zhong Wang1, Zhanyong Zhu2, Chenyuan Li1, Yimin Zhang3, Zhiyu Li4, Shengrong Sun5.   

Abstract

Non-muscle myosin IIA (NMIIA) has been reported to be involved in the carcinogenesis and malignant progression of various human tumors. However, the role and potential mechanism of NMIIA in the biological functions and apoptosis in colorectal cancer (CRC) remain elusive. In this study, we found that NMIIA was overexpressed in CRC tissues and significantly associated with poor survival in CRC patients. In addition, NMIIA promoted CRC cell proliferation and invasion via activating the AMPK/mTOR pathway in vitro, and NMIIA knockdown inhibited CRC growth in vivo. Meanwhile, NMIIA knockdown downregulated the CSCs markers (CD44 and CD133) expression in CRC cells. Furthermore, AMPK/mTOR pathway activation effectively reversed the NMIIA knockdown-induced inhibition of proliferation, invasion and stemness in CRC cells. Finally, NMIIA protects CRC cells from 5-FU-induced apoptosis and proliferation inhibition through the AMPK/mTOR pathway. Taken together, these results indicate that NMIIA plays a pivotal role in CRC growth and progression by regulating AMPK/mTOR pathway activation, and it may act as a novel therapeutic target prognostic factor in CRC.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMPK/mTOR pathway; CSCs markers; Cell survival; Colorectal cancer; NMIIA

Year:  2020        PMID: 33220257     DOI: 10.1016/j.yexcr.2020.112387

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

1.  Myh9 Plays an Essential Role in the Survival and Maintenance of Hematopoietic Stem/Progenitor Cells.

Authors:  Quanming An; Yong Dong; Yang Cao; Xu Pan; Yuan Xue; Ya Zhou; Yonggang Zhang; Feng Ma
Journal:  Cells       Date:  2022-06-07       Impact factor: 7.666

2.  PSMD12 promotes glioma progression by upregulating the expression of Nrf2.

Authors:  Zhongyong Wang; Zhiyu Li; Hui Xu; Yun Liao; Chao Sun; Yanming Chen; Minfeng Sheng; Qing Lan; Zhong Wang
Journal:  Ann Transl Med       Date:  2021-04

3.  MYH9 Facilitates Cell Invasion and Radioresistance in Head and Neck Cancer via Modulation of Cellular ROS Levels by Activating the MAPK-Nrf2-GCLC Pathway.

Authors:  Guo-Rung You; Joseph T Chang; Yan-Liang Li; Chi-Wei Huang; Yu-Liang Tsai; Kang-Hsing Fan; Chung-Jan Kang; Shiang-Fu Huang; Po-Hung Chang; Ann-Joy Cheng
Journal:  Cells       Date:  2022-09-13       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.